Impact BioMedical, INC. Stock-Based Compensation
Impact BioMedical, INC. (IBO) reported Stock-Based Compensation of $1.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-07
- Impact BioMedical, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Impact BioMedical, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.44M, a 71900.00% increase year-over-year.
- Impact BioMedical, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $8.00K.
- Impact BioMedical, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.00K.
- Impact BioMedical, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $13.00K, a 31.58% decline from fiscal 2024.
- Impact BioMedical, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $19.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.44M 10-Q · filed 2026-08-07 | $1.45M derived: sum of 3 quarters · filed 2026-08-07 | $1.45M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $1.44M 10-Q · filed 2026-05-12 | $1.45M derived: sum of 2 quarters · filed 2026-05-12 | $1.45M derived: sum of 3 quarters · filed 2026-05-12 | $1.45M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $9.00K derived: sum of 2 quarters · filed 2026-03-11 | $11.00K derived: sum of 3 quarters · filed 2026-08-07 | $13.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $3.00K derived: sum of 2 quarters · filed 2026-08-07 | $5.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $4.00K 10-Q · filed 2026-08-07 | ||
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $19.00K 10-K · filed 2026-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |